[ad_1] L & # 39; Ema Chmp adopted a positive opinion for the extension of the indications of rivaroxaban. The new indication approved as a preliminary point is as follows: rivaroxaban, co-administered …
Read More »
[ad_1] Ema Chmp gave a positive opinion for abemaciclib recommending its approval for the treatment of hormone receptor-positive bad cancer (HR +) and negative for the locally advanced human epidermal growth factor …
Read More »
[ad_1] Ema Chmp recommended the approval of a BRAF inhibitor, encorafenib, in combination with an MEK inhibitor, binimetinib, for the treatment of adult patients with melanoma with mutations BRAFV600 non-insoluble or metastatic. …
Read More »
[ad_1] For the treatment of hereditary amyloid transthyretin (hATTR), Ema Chmp has given the nod to the approval of patisiran, an experimental therapy that acts through the mechanism of RNA interference . …
Read More »